Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, efficacy (dose response) and pharmacokinetics of 0.3% and 1%
OPA-15406 when applied twice daily for 4 weeks in pediatric patients with atopic dermatitis.